Trends in antipsychotic prescribing practices in an urban community mental health clinic

REFERENCES

• Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry 2003; 37: 55–61.
   PubMed Web of Science ®Google Scholar
• Jablensky A, McGrath J, Herrman H . National Survey of Mental Health and Wellbeing. Report 4. People Living with Psychotic Illness: an Australian Study. Canberra: Commonwealth Department of Health and Aged Care, 1999.
   Google Scholar
• Keks NA, Altson K, Hope J . Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Australian and New Zealand Journal of Psychiatry 1999; 33: 896–901.
   PubMed Web of Science ®Google Scholar
• Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australasian Psychiatry 2000; 8: 220–224.
   Google Scholar
• Humberstone V, Wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Australian and New Zealand Journal of Psychiatry 2004; 38: 240–245.
   PubMed Web of Science ®Google Scholar
• Wheeler A. Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions. New Zealand Medical Journal 2006; 119.
   Google Scholar
• RANZCP Clinical Practice Guidelines Team. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005; 39: 1–30.
   Google Scholar
• Lambert TJR, Castle DJ. Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia 2003; 178: S57–S61.
   Google Scholar
• Lewis S, Lieberman J. CATIE and CUtLASS: Can we handle the truth? British Journal of Psychiatry 2008; 192: 161–163.
   PubMed Web of Science ®Google Scholar
• Lambert TJR, Chapman LH, Bell S . Diabetes, psychotic disorders and antipsychotic therapy: A consensus statement. Medical Journal of Australia 2004; 181: 544–548.
   PubMed Web of Science ®Google Scholar
• Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003; 36: 18–26.
   PubMedGoogle Scholar
• Lieberman JA. Comparative effectiveness of antipsychotic drugs. Archives of General Psychiatry 2006; 63: 1069–1072.
   PubMed Web of Science ®Google Scholar
• Cook PE, Goldberg JO, Van Lieshout RJ. Benefits of switching from typical to atypical antipsychotic medications: A longitudinal study in a community-based setting. Canadian Journal of Psychiatry 2002; 47: 870–874.
   PubMed Web of Science ®Google Scholar
• Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: A 2-year comparison. Journal of Clinical Psychiatry 2003; 64: 673–679.
   PubMed Web of Science ®Google Scholar
• Baune BT. New developments in the management of major depressive disorder and generalized anxiety disorder: Role of quetiapine. Neuropsychiatric Disease and Treatment 2008; 4: 1181–1192.
   PubMedGoogle Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003; 60: 553–564.
   PubMed Web of Science ®Google Scholar
• Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry 2002; 159: 1005–1010.
   PubMed Web of Science ®Google Scholar
• Fleurence RL, Chatterton ML, Dixon JM, Rajagopalan K. Economic outcomes associated with atypical antipsychotics in bipolar disorder: A systematic review. Primary Care Companion to the Journal of Clinical Psychiatry 2007; 9: 419–428.
   PubMedGoogle Scholar
• Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 2008; 10: 788–797.
   PubMed Web of Science ®Google Scholar
• Rosenberg RP. Sleep maintenance insomnia: Strengths and weaknesses of current pharmacologic therapies. Annals of Clinical Psychiatry 2006; 18: 49–56.
   PubMedGoogle Scholar
• Olson LG. Hypnotic hazards: Adverse effects of zolpidem and other z-drugs. Australian Prescriber 2008; 31: 146–149.
   Google Scholar